FDA approves Pfizer/Merck KGaA's Bavencio in first line bladder cancer
The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and AstraZeneca.
pharmaphorum.com